Compare Gilead Sciences, Inc. (GILD) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Wayfair Inc — how do they compare? Gilead Sciences, Inc. trades at $138.27 (market cap $171.29B), while Wayfair Inc trades at $105.52 (market cap $13.85B). The key difference: Gilead Sciences, Inc. is far larger — about 12.4× Wayfair Inc's market cap, and Gilead Sciences, Inc. pays a 2.37% dividend while Wayfair Inc pays none. Which is the better fit depends on your goals.
| GILD | W | |
|---|---|---|
Market Cap | $171.29B | $13.85B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $119.05 |
52-Week Low | $110.56 | $57.40 |
Enterprise Value | $194.35B | $16.19B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $138.14, up 1.75% in the last session, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong Q2 2026 revenue growth of 8% year-over-year, driven by HIV drug sales, though a net loss of $6.75 per share resulted from acquisition-related charges. Analyst consensus is strongly bullish with a $151.22 price target, while institutional activity shows mixed positioning adjustments.
The outlook for GILD is positive due to robust HIV franchise performance and raised 2026 guidance, but risks include patent cliffs by the mid-2030s and integration costs from acquisitions. The stock offers potential upside from pipeline advancements, though volatility may persist from earnings fluctuations and competitive pressures.
Wayfair (W) trades at $102.79, down 0.4% on the day, with a bullish technical outlook supported by a golden cross signal and strong support near $101. The company reported Q2 2026 earnings of $0.95 per share, beating estimates, with revenue growth of 7.5% year-over-year driven by U.S. demand. However, net income remains negative at -$321 million for 2026, reflecting ongoing profitability challenges despite top-line expansion.
The stock offers upside to the consensus price target of $122, with 52% of analysts rating it a buy, but risks include high debt-to-asset ratio of 95.11% and persistent net losses. Investor sentiment is buoyed by recent earnings beats and market share gains, yet macroeconomic pressures on consumer spending pose headwinds for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
